The Development Therapeutics Committee of the ECOG-ACRIN Cancer Research Group is responsible for developing trials of agents that target specific biologic pathways. In pursuing this goal, the committee develops strategies, trials, and programs that transect the classic disease-oriented approach. It coordinates its scientific development with the 11 disease-oriented scientific committees and working groups in the Therapeutic Studies Program.
With expertise in the early clinical development of novel targeted therapies, the Developmental Therapeutics Committee is in a unique position to facilitate the creation of a new stratum of trials. At least one representative from each disease-oriented committee or working group a member. Like the Laboratory Science and Pathology Committee, it also seeks experts in genetic, RNA, miRNA and protein-based assay development, regardless of their institution’s membership status in the Group.
Keith T. Flaherty, MD
Massachusetts General Hospital Cancer Center
Gary I. Cohen, MD
Greater Baltimore Medical Center, an affiliate of The Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University
|Cancer Control and Outcomes Program|
|Therapeutic Studies Program|
|Biomarker Sciences Program|